Early and accurate diagnosis is a priority in improving treatment response and in slowing down neurodegeneration and disease progression, regardless of outstanding advancements in therapeutics. Recent ...

Precision medicine has revolutionized the landscape of neurological care, shifting from “one-size-fits-all” approaches to ...

IPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial ...

As molecular biomarkers go, proteins are possibly the most universally affected by disease state. Protein signatures encompass not only total levels of expression, but predominance of different ...

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

In follow-up to the Forum on Neuroscience and Nervous System Disorders' March 2023 workshop on Multimodal Biomarker for Central Nervous System Disorders: Development, Integration and Clinical Utility, ...

For much of the past century, Alzheimer's disease has been one of medicine's most daunting frontiers—biologically complex, ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...